Roger Kitterman is a co-founder and a Managing Partner of Mass General Brigham Ventures and Vice President, Mass General Brigham. He joined Mass General Brigham Ventures at its founding in 2008 and played a significant role in the creation, early sourcing, financing, and development of the portfolio which includes 55 companies since inception and over $450 million in assets under management. Roger also leads the intellectual property and business development and licensing teams across Mass General Brigham that are responsible for commercialization from the over $2 billion in annual research across the system. Roger’s leadership role includes the oversight of several internal technology development programs which are focused on advancing novel technologies from internal research from the firm’s flagship hospitals with the overarching goal of improving health care and outcomes.
Roger began his venture capital career in Eastern Europe with the Bulgarian- American Enterprise Fund, a $55 million venture capital fund. He has also been the startup CEO for three venture-backed companies and is a founder of Mass Medical Angels. He has previously served as a partner at life science-focused venture funds in the Boston area. Roger is current on the Boards of Affinia Therapeutics and NControl Therapeutics and other notable early-stage investments include Adheron Therapeutics, CoStim Pharmaceuticals, Magenta Therapeutics, Spero Therapeutics, and Verve Therapeutics.
Roger holds an MBA in Finance and Business Development from the Columbia Business School and an AB from Harvard College.
Senior Vice President, Venture, Business Development and Licensing, Mass General Brigham
Join our email list to recieve exclusive offers